Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone

Xenobiotica

Volumn 27, Issue 3, 1997, Pages 243-256

  Gorski, J C ^a   Jones, D R ^a   Wrighton, S A ^b   Hall, S D ^a  

^a INDIANA UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 METHYLPYRAZOLE; ALPHA NAPHTHOFLAVONE; CHLORZOXAZONE; CYTOCHROME P450; DIETHYLDITHIOCARBAMIC ACID; ENZYME ANTIBODY; GESTODENE; ISOENZYME; MIDAZOLAM; OXYGENASE; TROLEANDOMYCIN;

ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; ENZYME ACTIVITY; ENZYME KINETICS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER METABOLISM; LIVER MICROSOME; NORMAL HUMAN;

ARYL HYDROCARBON HYDROXYLASES; CHLORZOXAZONE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; HYDROXYLATION; ISOENZYMES; KINETICS; MICROSOMES, LIVER; MUSCLE RELAXANTS, CENTRAL; OXIDOREDUCTASES, N-DEMETHYLATING;

ORYCTOLAGUS CUNICULUS; STAPHYLOCOCCUS PHAGE 3A;

EID: 0030895593     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982597240578     Document Type: Article

References (50)

1. ANDERSSON, T., MINERS, J. O., VERONESE, M. E. and BIRKETT, D. J., 1994, Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. British Journal of Clinical Pharmacology, 36, 597-604.
2. ANDERSSON, T., MINERS, J. O., VERONESE, M. E., TASSANEEYAKUL, W., TASSANEEYAKU, I. W., MEYER, U. A. and BIRKETT, D. J., 1993, Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. British Journal of Clinical Pharmacology, 36, 521-530.
3. BERTHOU, F., GOASDUFF, T., LUCAS, D., DRÉNO, Y., LE BOT, M.-H. and MÉNEZ, J.-F., 1995, Interaction between two probes used for phenotyping cytochrome P4501A2 (caffeine) and P4502E1 (chlorzoxazone) in humans. Pharmacogenetics, 5, 72-79.
4. BIENVENU, T., REY, E., PONG, G., D'ATHIS, P. and OLIVE, G., 1991, A simple non-invasive procedure for investigation of cytochrome P450 IIIA dependent enzymes in humans. International Journal of Clinical Pharmacology, Therapeutics, and Toxicology, 29, 441-445.
5. CARRIERE, V., GOASDUFF, T., RATANASAVANH, D., MOREL, F., GAUTIER, J-C., GUILLOUZO, A., BEAUNE, P. and BERTHOU, F., 1993, Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chemical Research in Toxicology, 6, 852-857.
6. CHANG, T. K. H., GONZALEZ, F. J. and WAXMAN, D. J., 1994, Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochrome P450. Archives of Biochemistry and Biophysics, 311, 437-442.
7. COON, M. J., KOOP, D. R., REEVE, L. E. and CRUMP, B. L., 1984, Alcohol metabolism and toxicity: role of Cytochrome P-450. Fundamental and Applied Toxicology, 4, 134-143.
8. FLEMING, C. M., BRANCH, R. A., WILKINSON, G. R. and GUENGERICH, F. P., Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4. Molecular Pharmacology, 41, 975-980.
9. FUNCK-BRETANO, C., THOMAS, G., JACQZ-AGRAIN E., POIRIER, J.-M., SIMON, T., BEREZIAT, G. and JAILLON, P., 1993, Polymorphism of dextromethorphan metabolism: Relationship between phenotype, genotype and response to the administration of encainide in humans. Journal of Pharmacology and Experimental Therapeutics, 263, 780-786.
10. GIRRE, J. M., LUCAS, D., HISPARD, E., MENEZ, C., DALLY, S., and MENEZ, J.-F., 1994, Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochemical Pharmacology, 47, 1503-1508.
11. GORSKI, J. C., JONES, D. R., WRIGHTON, S. A. and Hall, S. D., 1994a, Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochemical Pharmacology, 48, 173-182.
12. GORSKI, J. C., HALL, S. D., JONES, D. R., VANDENBRANDEN, M. and WRIGHTON, S. A., 1994b, Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochemcial Pharmacology, 47, 1643-1653.
13. GOTTENDORF, R. J., BRITTO, M., BLOUIN, R. A., FOSTER, T. S., JOHN, W., PITTMAN, K. A. and WEDLUND, P. J., 1990, Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism. British Journal of Clinical Pharmacology, 29, 373-380.
14. GUENGERICH, F. P., KIM, D.-H. and IWASAKI, M., 1991, Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chemical Research in Toxicology, 4, 168-179.
15. HALL, S. D., HAMMAN, M. A., RETTIE, A. E., WIENKERS, L. C., TRAGER, W. F., VANDENBRANDEN, M. and WRIGHTON, S. A., 1994, Relationship between the levels of cytochrome P450 2C9 and its prototypic catalytic activities in human liver microsomes. Drug Metabolism and Disposition, 22, 975-978.
16. IMAOKA, S., IMAI, Y., SHIMADA, T. and FUNAE, Y., 1992, Role of phospholipids in reconstituted cytochrome P450 3A form and mechanism of their activation of catalytic activity. Biochemistry, 31, 6063-6069.
17. INGELMAN-SUNDBERG, M., HAGBJÖRK, A.-L., UENG, Y.-F., YAMAZAKI, H. and GUENGERICH, F. P., 1996, High rates of substrate hydroxylation by human cytochrome P450 3A4 in reconstituted membranous vesicles: influences of membrane charge. Biochemical Biophysical Research Communications, 221, 318-322.
18. JAYYOSI, Z., KNOBLE, D., MUC, M., ERICK, J., THOMAS, P. E. and KELLEY, M., 1995, Cytochrome P-450 2E1 is not the sole catalyst of chlorzoxozone hydroxylation in rat liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 273, 1156-1161.
19. KERR, B. M., THUMMEL, K. E., WURDEN, C. J., KLEIN, S. M., KROETZ, D. L., GONZALES, F. J. and LEVY, R. H., 1994, Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochemical Pharmacology, 47, 1969-1979.
20. KHARASCH, E. D., THUMMEL, K. E., MHYRE, J. and LILLIBRIDGE, J. H., 1993, Single-dose disulfiram inhibition of chlorzoxazone metabolism: A clinical probe for P450 2E1. Clinical Pharmacology and Therapeutics, 53, 643-50.
21. KINIRONS, M. T., O'SHEA, D., DOWNING, T. E., FITZWILLIAM, A. T., JOELLENBECK, L., GROOPMAN, J. D., WILKINSON, G. R. and WOOD, A. J. J., 1993, Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clinical Pharmacology and Therapeutics, 54, 621-629.
22. KOLARS, J. C., LOWN, K. S., SCHMIEDLIN-REN, P., GHOSH, M., FANG, C., WRIGHTON, S. A., MERION, R. M. and WATKINS, P. B., 1994, CYP3A gene expression in human gut epithelium. Pharmacogenetics, 4, 247-259.
23. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
24. NEWTON, D. J., WANG, R. W., and LU, A. Y. H., 1995, Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158.
25. OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry, 239, 2370-2378.
26. ONO, S., HATAMAK, T., HOTTA, H., TSUTSUI, M., SATOH, T. and GONZALEZ, F. J., 1995, Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics, 5, 143-150.
27. PETER, R., BÖCKER, R., BEAUNE, P. H., IWASAKI, M., GUENGERICH, F. P. and YANG, C. S., 1990, Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chemical Research in Toxicology, 3, 566-573.
28. RAUTIO, A., KRAUL, H., KOJO, A., SALMELA, E. and PELKONEN, O., 1992, Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics, 2, 227-233.
29. 13C-(N-3-methyl)-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clinical Pharmacology Therapeutics, 52, 170-180.
30. SCHWAB, G. R., RAUCY, J. L. and JOHNSON, E. F., 1988, Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by α-naphthoflavone. Molecular Pharmacology, 33, 493-499.
31. SESARDIC, D., BOOBIS, A. R., MURRAY, B. P., MURRAY, S., SEGURA, J., DE LA TORRE, R. and DAVIES, D. S., 1990, Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man. British Journal of Clinical Pharmacology, 29, 651-663.
32. SHIMADA, T., YAMAZAKE, H., MIIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with liver microsomes from 30 Japanese and 30 caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
33. SHOU, M., GROGAN, J., MANCEWICZ, J. A., KRAUSZ, K. W., GONZALEZ, F. J., GELBOIN, H. V. and KORZEKWA, K. R., 1994, Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry, 33, 6450-6455.
34. SOHN, D.-R., KOBAYASH, K. I., CHIBE, K., LECK, K.-H., SHIN, S.-G. and ISHIZAKI, T., 1992, Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an oriental population. Journal of Pharmacology and Experimental Therapeutics, 262, 1195-1202.
35. SOKAL, R. R. and ROHLF, F. J., 1981, Biometry, 2nd edn (New York: W. H. Freeman).
36. TASSANEEYAKUL, W., BIRKETT, D. J., VERONESE, M. E., MCMANUS, M. E., TUKEY, R. H., QUARTTROCHI, L. C., GELBOIN, H. V., and MINERS, J. O., 1993, Specificity of substrate and inhibitor probes for human cytochromes P4501A1 and 1A2. Journal of Pharmacology and Experimental Therapeutics, 265, 401-407.
37. TASSANEEYAKUL, W., BIRKETT, D. J., MCMANUS, M. E., TASSANEEYAKUL, W., VERONESE, M. E., ANDERSSON, T., TUKEY, R. H. and MINERS, J. O., 1994, Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochemical Pharmacology, 47, 1767-1776.
38. TASSANEEYAKUL, W., VERONESE, M. E., BIRKETT, D. J., DOECKE, C. J., MCMANUS, M. E., SANSOM, L. N. and MINERS, J. O., 1992, Co-regulation of phenytoin and tolbutamide in humans. British Journal of Clinical Pharmacology, 34, 494-498.
39. THUMMEL, K. E., KHARASCH, E. D., PODOLL, T. and KUNZE, K., 1993, Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metabolism and Disposition, 21, 350-357.
40. VANDER HOEVEN, T. A. and COON, M. J., 1974, Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. Journal of Biological Chemistry, 249, 6302-6310.
41. WATKINS, P. B., MURRAY, S. A., WINKELMAN, L. G., HEUMAN, D. M., WRIGHTON, S. A. and GUZELIAN, P. S., 1989, Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in man and rat. Journal of Clinical Investigation, 83, 688-697.
42. WATKINS, P. B., WRIGHTON, S. A., MAUREL, P., SCHUETZ, E. G., MENDEZ-PICON, G., PARKER, G. A. and GUZELIAN, P. S., 1985, Identification of an inducible form of cytochrome P450 in human liver. Proceedings of the National Academy of Sciences, USA, 82, 6310-6314.
43. WRIGHTON, S. A., BRIAN, W. R., SARI, M-A., IWASAKI, M., GUENGERICH, F. P., RAUCY, J. L., MOLOWA, D. T. and VANDENBRANREN, M., 1990, Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Molecular Pharmacology, 38, 207-213.
44. WRIGHTON, S. A., RING, B. J., WATKINS, P. B. and VANDENBRANDEN, M., 1989, Identification of a polymorphically expressed member of the human cytochrome P-450III family. Molecular Pharmacology, 36, 97-105.
45. WRIGHTON, S. A., STEVENS, J. C., BECKER, G. W. and VANDENBRANDEN, M., 1993b, Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Archives of Biochemistry and Biophysics, 306, 240-245.
46. WRIGHTON, S. A., THOMAS, P. E., MOLOWA, D. T., HANIU, M., SHIVELY, J. E., MAINES, S. L., WATKINS, P. B., PARKER, G., MENDEZ-PICON, G., LEVIN, W. and GUZELIAN, P. S., 1986, Characterization of ethanol-inducible human liver N-nitrosodimethylamine demethylase. Biochemistry, 25, 6731-6735.
47. WRIGHTON, S. A., VANDENBRANDEN, M., STEVENS, J. C., SHIPLEY, L. A., RING, B. J., RETTIE, A. E. and CASHMAN, J. R., 1993a, In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metabolism Reviews, 25, 453-484.
48. YAMAZAKI, H., GUO, Z. and GUENGERICH, F. P., 1995, Selectivity of cytochrome P450 2E1 in chlorzoxazone 6-hydroxylation. Drug Metabolism and Disposition, 23, 438-440.
49. ZAND, R., NELSON, S. D., SLATTERY, J. T., THUMMEL, K. E., KALHORN, T. F., ADAMS, S. P. and WRIGHT, J. M., 1993, Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clinical Pharmacology Therapeutics, 54, 142-149.
50. ZILLY, W., BREIMER, D. D. and RICHTER, E., 1977, Stimulation of drug metabolism by rifampin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance. European Journal of Clinical Pharmacology, 11, 287-293.